A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Active surveillance is a standard approach for managing men with low‑risk prostate cancer to help delay or avoid treatment, but a significant number of patients eventually experience disease ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical ...

Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...

Doctors followed standard testing guidelines, which recommend discontinuing screenings for men over 70 years old. Should that ...

Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...